Cytek Biosciences (CTKB) vs Rapid Micro Biosystems (RPID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed Rapid Micro Biosystems (RPID) over the past year, gaining 4.1% versus a loss of 82.4%. Over five years, CTKB leads with a -67.8% price change compared with -94.4% for RPID. Cytek Biosciences is the larger company by market cap ($800.4 million vs $37.4 million), about 21.4 times the size, while Rapid Micro Biosystems is growing revenue faster (+19.7% vs +0.5%).
Cytek Biosciences converts more of its revenue into profit, with a net margin of -33.0% versus -140.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | RPID |
|---|---|---|
| Share price | $6.12 | $0.735 |
| Market cap | $800.40M | $37.37M |
| 1-day change | -3.16% | -0.04% |
| YTD return | +21.19% | -74.66% |
| 1-year return | +4.08% | -82.37% |
| 5-year return | -67.82% | -94.41% |
| Forward P/E | 87.43 | — |
| EPS (TTM) | $-0.63 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $201.49M | $33.59M |
| Revenue growth (YoY) | +0.52% | +19.74% |
| Net income (latest FY) | $-66.54M | $-47.12M |
| Gross margin | 51.84% | — |
| Operating margin | -20.04% | -141.10% |
| Net margin | -33.02% | -140.30% |
| 52-week high | $6.39 | $4.94 |
| 52-week low | $3.31 | $0.58 |
| Distance from 52-week high | -4.15% | -85.12% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +6.21% | +682.31% |
| Average volume | 1.31M | 577.05K |
| Shares outstanding | 130.78M | 46.34M |
| Employees | 703 | 171 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cytek Biosciences is about 21.4 times larger than Rapid Micro Biosystems by market value ($800.40M vs $37.37M).
- CTKB has outperformed RPID by 86.5 percentage points over the past year.
- Cytek Biosciences is more profitable, keeping -33.0 cents of every revenue dollar as net income versus -140.3 cents for Rapid Micro Biosystems.
- Rapid Micro Biosystems grew revenue faster in its latest fiscal year (+19.74% vs +0.52%).
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 703 employees
About Rapid Micro Biosystems
RPID stock →Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 171 employees
CTKB vs RPID FAQ
Which is bigger, Cytek Biosciences or Rapid Micro Biosystems?
Cytek Biosciences (CTKB) is larger, with a market capitalization of $800.40M compared with $37.37M for Rapid Micro Biosystems (RPID).
Which stock has performed better over the past year, CTKB or RPID?
CTKB returned +4.08% over the past 12 months, compared with -82.37% for RPID (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and Rapid Micro Biosystems in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.